Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
Authors
Yang C, Wang W, Deng P, Wang X, Zhu L, Zhao L, Li C, Gao H
Journal
CNS neuroscience & therapeutics
Year
2023
Keywords:
FGF21, Parkinson's disease, metabolism, microbiota-gut-brain metabolic axis, neurotransmitter
AIMS: The effects of FGF21 on Parkinson's disease (PD) and its relationship with gut microbiota have not been elucidated. This study aimed to investigate whether FGF21 would attenuate behavioral impairment through microbiota-gut-brain metabolic axis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced PD mice model. METHODS: Male C57BL/6 mice were rendomized into 3 groups: vehicle (CON); MPTP 30 mg/kg/day i.p. injection (MPTP); FGF21 1.5 mg/kg/d i.p. injection plus MPTP 30 mg/kg/day i.p. injection (FGF21 + MPTP). The behavioral features, metabolimics profiling, and 16 s rRNA sequencing were performed after FGF21 treatment for 7 days. RESULTS: MPTP-induced PD mice showed motor and cognitive deficits accompanied by gut microbiota dysbiosis and brain-region-specific metabolic abnormalities. FGF21 treatment dramatically attenuated motor and cognitive dysfunction in PD mice. FGF21 produced a region-specific alteration in the metabolic profile in the brain in ways indicative of greater ability in neurotransmitter metabolism and choline production. In addition, FGF21 also re-structured the gut microbiota profile and increased the relative abundance of Clostridiales, Ruminococcaceae, and Lachnospiraceae, thereby rescuing the PD-induced metabolic disorders in the colon. CONCLUSION: These findings indicate that FGF21 could affect behavior and brain metabolic homeostasis in ways that promote a favorable colonic microbiota composition and through effects on the microbiota-gut-brain metabolic axis.
Experiment 1
Needs review
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Mus musculus
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Colon Hindgut,Large bowel,Posterior intestine,Colon,colon
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Parkinson's disease IDIOPATHIC PARKINSON DIS,Idiopathic Parkinson Disease,Idiopathic Parkinson's Disease,IDIOPATHIC PARKINSONS DIS,Idiopathic PD,LEWY BODY PARKINSON DIS,Lewy Body Parkinson Disease,Lewy Body Parkinson's Disease,Paralysis agitans,paralysis agitans,PARKINSON DIS,PARKINSON DIS IDIOPATHIC,Parkinson disease,Parkinson Disease, Idiopathic,Parkinson syndrome,Parkinson's,Parkinson's disease,Parkinson's disease (disorder),Parkinson's disease NOS,Parkinson's disease NOS (disorder),Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinson's syndrome,Parkinsonian disorder,Parkinsonism, Primary,Parkinsons,PARKINSONS DIS,PARKINSONS DIS IDIOPATHIC,PARKINSONS DIS LEWY BODY,Parkinsons disease,Primary Parkinsonism,parkinson's disease
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Control (CON groups)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- MPTP (untreated PD mice)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Neurodegenerative disease characterized by both motor symptoms like rigidity and resting tremor as well as non-motor symptoms like depression and cognitive dysfunction
- Group 0 sample size Number of subjects in the control (unexposed) group
- 10
- Group 1 sample size Number of subjects in the case (exposed) group
- 10
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Ion Torrent
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 4
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Needs review
Source: Figure 5A, Text
Description: LEfSe analysis with LDA score representing statistical bacterial differences in colonic microbiota between the PD (positive score) and CON groups (negative score).
Abundance in Group 1: increased abundance in MPTP (untreated PD mice)
| NCBI | Quality Control | Links |
|---|---|---|
| Muribaculaceae | ||
| Bacteroidaceae | ||
| Bacteroides | ||
| Prevotellaceae | ||
| Alloprevotella | ||
| Tannerellaceae | ||
| Parabacteroides |
Revision editor(s): Fiddyhamma
Signature 2
Needs review
Source: Figure 5A, Text
Description: LEfSe analysis with LDA score representing statistical bacterial differences in colonic microbiota between the PD (positive score) and CON groups (negative score).
Abundance in Group 1: decreased abundance in MPTP (untreated PD mice)
Revision editor(s): Fiddyhamma
Experiment 2
Needs review
Differences from previous experiment shown
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Clinical treatment Clinical treatment,clinical treatment
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- FGF21 + MPTP mice (mice treated with Fibroblast growth factor 21 (FGF21))
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Richness Number of species
- increased
Signature 1
Needs review
Source: Figure 5C, Text
Description: LEfSe analysis with LDA score representing statistical bacterial differences in colonic microbiota between the PD (positive score) and FGF21 groups (negative score).
Abundance in Group 1: increased abundance in MPTP (untreated PD mice)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacillales | ||
| Mammaliicoccus lentus | ||
| Staphylococcaceae | ||
| Staphylococcus |
Revision editor(s): Fiddyhamma
Signature 2
Needs review
Source: Figure 5C, Text
Description: LEfSe analysis with LDA score representing statistical bacterial differences in colonic microbiota between the PD (positive score) and FGF21 groups (negative score).
Abundance in Group 1: decreased abundance in MPTP (untreated PD mice)
Revision editor(s): Fiddyhamma
Retrieved from "https://bugsigdb.org/w/index.php?title=Study_961&oldid=123455"
Hidden category:
